摘要
目的:系统评价紫杉醇联合顺铂辅助治疗中、晚期宫颈癌的近期疗效和安全性,以为临床治疗提供循证参考。方法:计算机检索中国期刊全文数据库、万方数据库、中文科技期刊数据库、Cochrane图书馆、EMBase,收集紫杉醇联合顺铂+手术治疗(试验组)对比其他方式(对照组)治疗中、晚期宫颈癌的随机对照试验(RCT),提取资料并评价质量后,采用Rew Man 5.0统计软件进行Meta分析。结果:共纳入9项RCT,合计1 097例患者。Meta分析结果显示,试验组患者总有效率[OR=4.12,95%CI(2.91,5.83),P<0.001]显著高于对照组,胃肠道反应发生率[OR=0.22,95%CI(0.10,0.47),P<0.001]和脱发发生率[OR=0.48,95%CI(0.24,0.95),P=0.03]显著低于对照组,两组患者骨髓抑制发生率[OR=1.02,95%CI(0.37,2.79),P=0.97]和过敏反应发生率[OR=1.87,95%CI(0.18,19.18),P=0.60]比较,差异无统计学意义。结论:紫杉醇联合顺铂辅助治疗中、晚期宫颈癌具有良好的近期疗效,可以减少患者不良反应的发生,降低并发症,安全性亦较好。受纳入研究方法学质量的限制,该结论有待高质量、大样本的RCT进一步验证。
OBJECTIVE： To systematically review the short-term efficacy and safety of paclitaxel combined with cisplatin in the treatment of advanced cervix cancer, and to provide evidence-based reference for clinical treatment. METHODS： Retrieved from CJFD,Wanfang database, VIP datebase, Cochrane library and EMBase, the randomized controlled trials （RCT） of paclitaxel＋ cisplatin （test group） versus surgery alone and / or combined with cisplatin （control group） in the treatment of advanced cervix cancer were collected, and Meta-analysis was performed by using Rev Man 5.0 statistics software after extracting data and evaluating quality. RESULTS： A total of 9 RCTs were enrolled, involving 1 097 patients. Results of Meta-analysis showed total effective rate [OR= 4.12,95 % CI （2.91,5.83 ）, P〈 0.001] in test group was significantly higher than control group, incidence of gastrointestinal reactions [OR = 0.22,95 % CI （ 0.10,0.47 ）, P〈 0.001 ] and incidence of alopecia [OR = 0.48, 95 % CI （ 0.24,0.95 ）, P = 0.03] were significantly lower than control group; there were no significant differences in the incidence of myelosuppression [RR=1.02,95% CI （0.37,2.79） ,P=0.97] and incidence of allergic reaction[OR= 1.87,95%CI（0.18, 19.18）,P=0.60] between 2 groups. CONCLUSIONS ： Paclitaxel combined with cisplatin has good short-term efficacy in the treatment of advanced cervix cancer, can reduce the incidence of adverse reactions and complications, with good safety. Due to the limit of research methodological quality, high quality and large-scale RCTs are required for further validation of the conclusions.
出处
《中国药房》
CAS
北大核心
2015年第24期3389-3392,共4页
China Pharmacy
关键词
紫杉醇
顺铂
宫颈癌
近期疗效
并发症
安全性
Paclitaxel
Cisplatin
Cervical cancer
Short-term efficacy
Complication
Safety
